<b>Conclusion:</b> This result confirmed that PARPis were effective for metastatic cSCC patients with germline BRCA2 pathogenic mutations and provided a new treatment option for this group of patients. The gene discussed is BRCA2; the disease is skin squamous cell carcinoma.